HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

Simple item page
dc.contributor.authorHaskelberg, H.
dc.contributor.authorCordery, D.
dc.contributor.authorAmin, J.
dc.contributor.authorKelleher, A.
dc.contributor.authorCooper, D.
dc.contributor.authorEmery, S.
dc.contributor.editorWinston, A.
dc.date.issued2014
dc.description.abstractBackground: There are limited data regarding the influence of human leukocyte antigen (HLA) polymorphisms on reduced bone mineral density (BMD). We investigated the relationship between HLA supertypes and BMD in HIV-infected adults changing their existing treatment to tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine (ABC-3TC) in the STEAL study. Methods: Lumbar spine and right hip BMD were measured by Dual-energy X-ray absorptiometry (DXA). HLA genotypes at the 2-digit level were classified into class I and II supertypes. Student’s t-tests were used to test the association between HLA supertypes and changes in hip and spine BMD over 96 weeks for the whole cohort and stratified by randomised groups. The relationship between HLA supertypes and BMD was also assessed in the subgroup of participants that were naı¨ve to both ABC and TDF at study entry. Results: Class II supertypes were mainly associated with hip BMD change. Overall, compared to participants not carrying HLA-DQ3, participants expressing DQ3 had less bone loss over 96 weeks at both the hip and spine (hip: 0.003 vs. –0.006 g/ cm², 95%CI 0.002 to 0.017, p = 0.016; spine: 0.006 vs. –0.006 g/cm², 95%CI 0.001 to 0.023, p = 0.041). In participants that were naïve to both ABC and TDF at baseline and randomised to TDF-FTC, DQ3 was significantly associated with less bone loss compared with those not carrying DQ3 (hip: 0.001 vs. –0.032 g/cm²; diff 0.033; 95%CI 0.017 to 0.049; p,0.001; spine: 0.007 vs. –0.023 g/cm²; diff 0.035; 95%CI 0.014 to 0.056; p = 0.001).
dc.description.statementofresponsibilityHila Haskelberg, Damien V. Cordery, Janaki Amin, Anthony D. Kelleher, David A. Cooper, Sean Emery, on behalf of the STEAL Study Group
dc.identifier.citationPLoS ONE, 2014; 9(3):e93333-1-e93333-7
dc.identifier.doi10.1371/journal.pone.0093333
dc.identifier.issn1932-6203
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/2440/113367
dc.language.isoen
dc.publisherPublic Library of Science (PLoS)
dc.rights© 2014 Haskelberg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.source.urihttps://doi.org/10.1371/journal.pone.0093333
dc.subjectSTEAL Study Group
dc.subjectHumans
dc.subjectHIV-1
dc.subjectHIV Infections
dc.subjectAdenine
dc.subjectDeoxycytidine
dc.subjectLamivudine
dc.subjectDideoxynucleosides
dc.subjectHLA-DQ Antigens
dc.subjectDrug Combinations
dc.subjectAnti-HIV Agents
dc.subjectAntiretroviral Therapy, Highly Active
dc.subjectBone Density
dc.subjectAlleles
dc.subjectAdult
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectOrganophosphonates
dc.subjectTenofovir
dc.subjectEmtricitabine
dc.titleHLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_113367.pdf
Size:
959.44 KB
Format:
Adobe Portable Document Format
Description:
Published Version
Download

Collections

Medicine publications